Oxidant stress is involved in the events that accompany endothelial cell ex
pression of adhesion molecules and leukocyte adherence in many disease stat
es, including atherosclerosis. A recently discovered benzo(b)pyran-4-one de
rivative, S17834 (10 to 50 mu mol/L), reduced tumor necrosis factor-stimula
ted vascular cell adhesion molecule-1 (VCAM) mRNA accumulation and protein
expression in human umbilical vein endothelial cells. Intercellular cell ad
hesion molecule-1 and E-selectin were also inhibited by S17834, but platele
t endothelial cell adhesion molecule-1 was not. Adherence of U937 monocytic
cells to the endothelial cells as well as to plastic plates coated with so
luble VCAM, intercellular cell adhesion molecule-1, P-selectin, and E-selec
tin was also decreased. Consistent with an antioxidant mechanism of action,
S17834 (10 to 50 mu mol/L) inhibited tumor necrosis factor-stimulated rele
ase of superoxide from endothelial cells measured by cytochrome c reduction
. S17834 had no effect on superoxide produced by xanthine oxidase, indicati
ng that rather than by acting as a scavenger of superoxide anion, the drug
acts by inhibiting the production of free radicals. Indeed, S17834 inhibite
d NADPH oxidase activity of endothelial cell membranes. The ability to inhi
bit superoxide anion production appears to be key in the effect of S17834 o
n superoxide anion production and VCAM expression, because these actions we
re mimicked by adenovirus-mediated overexpression of superoxide dismutase.
Furthermore, these actions may be relevant in vivo, because S17834 reduced
aortic superoxide anion levels by 40% and aortic atherosclerotic lesions by
60% in apolipoprotein E-deficient mice. These results indicate that S17834
inhibits adhesion molecule expression and adherence of leukocytes to endot
helial cells as well as aortic atherogenesis and that perhaps these effects
can be explained by its ability to inhibit endogenous superoxide anion pro
duction.